EGFR and breast cancer: For instance, suppression of SHIP2 promotes cell proliferation and metastasis by interacting with c-cbl and influencing epidermal growth factor receptor (EGFR) turnover, thereby enhancing EGF-induced Akt activation in breast cancer [21–23].